This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Genetherapyresearch is exciting and full of promise, but because of the risks involved, it’s also highly regulated, requiring an institutional biosafety committee (IBC) to provide additional oversight and risk assessment. IRBs are tasked with protecting research subject’s rights and welfare. What Does an IBC Review?
Genetherapyresearch is booming in the clinical setting. In this blog, we summarize the growth, risks, and regulatory requirements for genetherapyresearch. We also discuss how a centralized biosafety review process can benefit this type of research.
Research in genetherapies and geneticallyengineered drugs and vaccines are growing exponentially, and will only continue to become more popular. The accelerating genetherapy market is expected to grow globally by 16.6% between 2020-2027.
As Nick Spittal states in this Advarra press release, membership in the GeneTherapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.”
Innovation S-curve for the pharmaceutical industry Transcription factors for AAV is a key innovation area in pharmaceutical Adeno-associated virus (AAV) vectors are widely used for genetherapy. There are two main genes in the AAV genome, rep and cap, which encode nine different proteins.
Treatment involving a single injection has long-lasting effects BOSTON – Researchers have used a geneticengineering strategy to dramatically reduce levels of tau–a key protein that accumulates and becomes tangled in the brain during the development of Alzheimer’s disease–in an animal model of the condition.
Geneticallyengineered products often require additional safety practices to ensure the infectious agents do not endanger participants, study staff, or the broader environment where such agents are administered. How can I protect myself from exposure? What should I do if I’m exposed?
A new study has found that a novel T cell geneticallyengineered by University of Arizona Health Sciences researchers is able to target and attack pathogenic T cells that cause Type 1 diabetes, which could lead to new immunotherapy treatments.
The use of engineeredgenetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and genetherapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineeredgenetic materials.
Rapid growth in genetherapy is expected to receive additional support as the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) prepares to launch Operation Warp Speed for Rare Diseases. Peter Marks, head of FDA’s CBER – the organization responsible for regulating genetherapies.
Texas A&M AgriLife researchers’ work to aid mosquito control efforts To control mosquito populations and prevent them from transmitting diseases such as malaria, many researchers are pursuing strategies in mosquito geneticengineering.
The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.
The applications of gene switch platforms can be broadly classified into the following two categories: Endogenous Gene Regulation Exogenous Gene Regulation Endogenous Gene Regulation The ability to regulate endogenous genes has various applications in biological research and genetherapy development.
It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent.
Turkish researchers reported interim data on the same vaccine in December showing 91.25% efficacy. FBX-101 is a first-in-human AAV genetherapy. Krabbe disease is a rare and fatal pediatric leukodystrophy caused by mutations in the galactosylceramidase (GALC) gene. It also completely prevented severe cases.
Some have argued bacteria are developing antibiotic resistance faster than we can research, develop, test and approve new antibiotics. While developing an entirely new class of antibiotic is challenging, making minor genetic modifications to a virus or phage is something fairly easily accomplished with modern technologies.
These resources allow for scalable cell therapy production, ensuring affordability and broader access. Poseida’s geneticengineering platforms stand out for their precision, safety and potential to open new therapeutic avenues. Meanwhile, Novartis acquired Kate Therapeutics in a $1.1
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content